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Abstract 
A high-flow nasal cannula (HFNC) is a newly developed device that enables high-flow oxygen therapy for patients 
with serious cardiopulmonary problems, but there are few data regarding its use in patients with hematological dis-
ease. The efficacy and tolerability of HFNCs for patients who developed ARF during the treatment of various hema-
tological diseases was evaluated. Fifty-six patients underwent HFNC therapy during the last 2 years, and the causes 
of ARF were mainly pneumonia (n = 37) or acute congestive heart failure (n = 7). Only 11 patients (20 %) showed a 
good response to HFNC therapy, and remaining 45 patients (80 %) failed to respond to the initial HFNC therapy and, 
therefore, underwent second-line therapy including endotracheal intubation with mechanical ventilation (n = 15), 
non-invasive positive pressure ventilation (n = 1), or narcotic palliation alone (n = 29). Thus, HFNC appear not to be 
a viable treatment option in 4 out of 5 patients in this cohort of patients with hematological disease, but it was well 
tolerated in most patients (96 %); no major complications except for nasal soreness (n = 2) were observed. Multivari-
ate analysis showed that the cause of ARF (pneumonia, odds ratio 11.2, 95 % CI 1.76–71.5, p = 0.01) was the only risk 
factor for treatment failure.
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Background
Patients with hematologic diseases often develop acute 
respiratory failure (ARF) as a result of intensified therapy 
or subsequent immunosuppression (Schuster and Marion 
1983). Based on the current understanding, non-invasive 
positive pressure ventilation (NPPV) might provide more 
favorable outcomes, especially for immunocompromised 
patients, than conventional invasive ventilation (Azou-
lay et al. 2001; Antonelli et al. 1998; Depuydt et al. 2004; 
Soares et al. 2005; Hilbert et al. 2001). Recently, a high-
flow nasal cannula (HFNC) has been introduced as a 
new, non-invasive device, which not only supplies a high 
concentration of oxygen, but also generates a low level of 
positive airway pressure (PEEP; positive end-expiratory 
pressure) (Roca et al. 2010; Ward 2013; Parke et al. 2011; 
Corley et  al. 2011). Moreover, it can reduce ventilatory 
requirements by flushing the anatomical dead space with 
high-concentration oxygen, and well-humidified oxy-
gen may facilitate secretion clearance (Roca et  al. 2010; 
Ward 2013). Thus, this device would have many advan-
tages over conventional oxygen therapy or NPPV, and, 
therefore, it has been assessed in various clinical settings 
(Chatila et al. 2004; Carratalá Perales et al. 2011; Messika 
et al. 2015; Sztrymf et al. 2011, 2012). However, there are 
few data about its use in hematological disorders, espe-
cially in a low platelet count setting (Gristina et al. 2011; 
Peters et al. 2013; Kang et al. 2015). A retrospective study 
to evaluate the efficacy, safety, and tolerability of HFNC 
therapy in patients with hematological diseases was per-
formed at a single institution.
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Method and definitions
A retrospective chart review was performed to evaluate 
adult patients with various hematologic diseases who 
underwent HFNC therapy for treatment of ARF at our 
institution between October 2012 and September 2015. 
ARF was diagnosed when the patient met one of the fol-
lowing criteria under the condition of receiving oxygen 
supplementation at more than 4  L/min: oxygen satura-
tion level <90 %; respiratory rate more than 25 breaths/
min; and obvious signs of respiratory distress such as 
dyspnea, accessory-muscle use, and diaphoresis (Parke 
et  al. 2011). Successful HFNC treatment was defined as 
when patients had been weaned from the HFNC with-
out exacerbation of ARF. Treatment failure was sim-
ply defined as patients who failed to respond to HFNC 
therapy and underwent second-line therapy, including 
endotracheal intubation with mechanical ventilation or 
NPPV, or died on HFNC. HFNC therapy was judged as 
tolerable when patients had no HFNC-derived distress. 
The HFNC device (Optiflow™, MR850™ system, Fisher 
& Paykel Health-care, Auckland, New Zealand) consists 
of an air-oxygen blender, supplying an accurate fraction 
of delivery oxygen (FDO2) between 0.21 and 1.0, and a 
heated humidifier that allows the delivery of up to 60 L/
min. This system should maintain the inspired gas at a 
temperature of 37 °C and an absolute humidity of 44 mg 
H2O/L (Roca et al. 2010). All patients were supplied with 
a median 10 L/min (range 4–20 L/min) of supplemental 
oxygen via nasal cannula or facial mask before putting 
on the HFNC. The initial HFNC settings were: median 
FDO2 60 % (range 30–100 %); median HFNC flow 40 L/
min (range 15–60 L/min); and median duration of HFNC 
therapy 88 h (range 1–950 h).
This study was approved by the institutional ethics 
committee of our institution.
Statistical analysis
To evaluate the risk factors for HFNC treatment failure, 
the following categorical variables were used: age, sex, 
disease condition, the cause of ARF (pneumonia or not), 
neutropenia <500/µL, thrombocytopenia <30,000/µL, 
FDO2, concomitant clinical conditions including acute 
kidney injury, liver dysfunction, or allogeneic hemat-
opoietic stem cell transplantation (allo-HSCT), past 
clinical history including allo-HSCT, heart diseases, or 
pulmonary diseases, and the amount of delivered oxygen 
via nasal cannula or facial mask before starting HFNC 
therapy. Variables with p  <  0.10 were entered into the 
full model. On univariate analyses, Fisher’s exact tests 
(categorical variables) or Mann–Whitney U tests (con-
tinuous variables) were carried out. Multivariate logistic 
regression analysis was performed by a forced entry, and 
both odds ratios and associated 95 % confidence intervals 
(95  % CI) were calculated. In comparison of vital signs 
before and after initiating HFNC, Wilcoxon signed-rank 
test was carried out in terms of heart rate, oxygen satura-
tion, and respiratory rate. All p values were two-sided. p 
values <0.05 were considered significant.
Results
During the last 3 years, 56 patients eventually underwent 
HFNC treatment for ARF in our institution. The median 
age was 59  years (range 24–82  years), and 38 patients 
were men (68  %). The underlying diseases were mostly 
hematologic malignancies and other clinical characteris-
tics are summarized in Table 1.
Outcomes of HFNC
Eleven patients (20 %) responded well to HFNC therapy 
and were successfully weaned from the HFNC without 
exacerbation of ARF, while 45 patients (80  %) failed to 
respond to initial HFNC therapy; they therefore under-
went second-line therapy including endotracheal intuba-
tion with mechanical ventilation (n = 15), NPPV (n = 1), 
or narcotic palliation (n =  29). One patient with NPPV 
subsequently underwent endotracheal intubation with 
mechanical ventilation because of progressive hypoxia; 
therefore, 16 patients (29  %) eventually underwent 
endotracheal intubation with mechanical ventilation. 
However, only four of the patients undergoing mechanical 
ventilation survived. Thus, a total of 15 patients (27 %), 11 
patients with HFNC and four patients with endotracheal 
intubation with mechanical ventilation, survived ARF.
Results of univariate and multivariate analyses of the 
risk factors for treatment failure are shown in Table  2. 
On univariate analyses, neutropenia and low platelet 
count (<3.0 × 104/μL) at the onset of ARF, cause of ARF 
(pneumonia), and concomitant clinical condition of allo-
HSCT were significantly related to the risk of treatment 
failure, whereas age, sex, disease risk, concomitant dis-
ease or condition except for allo-HSCT, past clinical dis-
ease or condition, and oxygen supplement volume before 
starting HFNC therapy (>10 L/min), FDO2 were not sig-
nificant. Multivariate analysis with logistic regression 
identified the cause of ARF (pneumonia, odds ratio 11.2, 
95  % CI 1.76–71.5, p =  0.01) as the only risk factor for 
treatment failure (Table 2).
Comparison of vital signs before and after initiating 
HFNC was shown in Fig. 1. Median heart rate (n = 44), 
oxygen saturation level (n  =  50), and respiratory rate 
(n  =  27) of patients with ARF before initiating HFNC 
were 109/min, 91.5 %, 28/min, respectively. These param-
eters were significantly improved after initiating HFNC. 
Median heart rate, oxygen saturation level, respiratory 
rate were 102/min (p  <  0.01), 97  % (p  <  0.01), 25/min 
(p < 0.01), respectively.
Page 3 of 6Harada et al. SpringerPlus  (2016) 5:512 
Table 1 Characteristics of patients who underwent HFNC therapy
HFNC high-flow nasal cannula, AML acute myeloid leukemia, ALL acute lymphoid leukemia, MDS myelodysplastic syndrome, CMML chronic myelomonocytic leukemia, 
CMLBC chronic myeloid leukemia blast crisis, ATLL adult T cell leukemia and lymphoma, NHL non-Hodgkin’s lymphoma, PLL prolymphocytic leukemia, ITP idiopathic 
thrombocytopenic purpura, SAA severe aplastic anemia, ARF acute respiratory failure, GVHD graft-versus-host disease, WBC white blood cell, FDO2 fraction of delivery 
O2
a Disease risk was classified into two categories; high risk included acute leukemia not in remission, myelodysplastic syndrome with excess blast count, chronic 
myelomonocytic leukemia, or chronic myeloid leukemia blast crisis, the others were classified as low-risk
b Acute kidney injury was defined as having serum creatinine ≥1.5× upper limit of normal (ULN), or more than 0.3 points higher than baseline
c Liver dysfunction was defined as having serum aspartate aminotransferase/alanine aminotransferase ≥3× ULN, or total bilirubin ≥1.5× ULN (CTCAE ver. 4: grade 2)
d Past cardiac disease included atrial fibrillation, chronic congestive heart failure
e Past pulmonary disease included chronic obstructive pulmonary disease, bronchiolitis obliterans, forced expiratory volume% in 1 s ≤80 %, or diffusing capacity for 
carbon monoxide ≤80 %
Number (n) 56
Median age, years (range) 59 (24–82)
Sex (male/female) 38/18











Disease riska (high/low) 33/23
Cause of ARF (n)
 Pneumonia 37
 Congestive heart failure 7
 Organized pneumonia 4
 Pulmonary chronic GVHD 2
 Leukemic pulmonary invasion 2
 Multiple organ failure 2
 No identifiable cause 2
Median number of WBC (/μL) at the onset of ARF (range) 1850 (10–398,300)
Neutropenia (<500/μL)at the onset of ARF (yes/no) 32/24
Median number of platelet at the onset of ARF (×104/μL) (range) 2.8 (0.2–28.8)
Concomitant clinical condition
 Acute kidney injuryb (yes/no) 35/21
 Liver dysfunctionc (yes/no) 14/42
 Allogeneic hematopoietic stem cell transplantation (yes/no) 26/30
Past clinical history
 Cardiac diseased (yes/no) 5/51
 Pulmonary diseasee (yes/no) 8/48
 Allogeneic hematopoietic stem cell transplantation (yes/no) 42/14
Median oxygen supplement volume before putting HFNC (L/min) (range) 10 (4–20)
HFNC setting
 Median FDO2 (%) (range) 60 (30–100)
 Median flow (L/min) (range) 40 (15–60)
 Median time used (h) (range) 88 (1–950)
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Discussion
In the present cohort including a small number of 
patients evaluated retrospectively, HFNC therapy was 
well tolerated even in patients under or after allo-HSCT 
who were profoundly immunosuppressed or had low 
platelet counts and it significantly improved clinical 
vital signs of heart rate, oxygen saturation, and respira-
tory rate; however, the success rate was only 20  %, and 
45 patients (80  %) subsequently underwent second-line 
therapy. The present success rate was low compared to 
previous reports in which it was up to 90  % (Messika 
et al. 2015; Peters et al. 2013; Parke et al. 2011; Frat et al. 
2015). We assume that the discrepancy is likely attribut-
able to different patient background characteristics. The 
present patients were severely ill, with a high simpli-
fied acute physiology score (SAPS) II (median 43, range 
14–88) (Antonelli et  al. 1998; Hilbert et  al. 2000, 2001; 
Gristina et  al. 2011). Moreover, most patients had con-
comitant medical conditions, including acute kidney 
injury (n  =  35) or liver dysfunction (n  =  14), or were 
under allo-HSCT (n = 26), as shown in Table 1. In addi-
tion, since patients who underwent palliation or died 
on HFNC were classified as a non-responder to HNFC 
regardless to the response to HFNC, we might underesti-
mate the efficacy of HFNC.
Several reports have shown that invasive ventilation 
might be a risk factor for poor outcomes, especially in 
critically ill cancer patients; such patients are currently 
more likely to undergo non-invasive ventilation as initial 
treatment for ARF. However, few studies have directly 
compared the therapeutic efficacy of HFNC and NPPV. 
Kugelman et al. (2015) reported comparable data for the 
subsequent intubation rate between HFNC and NPPV 
therapy in neonatal patients. Frat et al. (2015) compared 
the intubation rate with conventional oxygen therapy, 
HFNC, or NPPV in a study. There were no differences in 
the intubation rate among the three groups. Focusing on 
selected patients who could be treated with PaO2/FiO2 
ratios of < 200, a significant difference in the subsequent 
intubation rate between HFNC and other modalities was 
observed. In addition, the ICU mortality rate at 28 days 
was significantly lower with HFNC therapy (Frat et  al. 
2015).
Although two patients gave up HFNC therapy due to 
either agitation or restlessness, the HFNC was well tol-
erated in the remaining patients (96  %), and no major 
adverse events, such as nasal mucosal hemorrhage or 
necrosis, were observed, even though most patients had 
a low platelet count (median 3.5 × 104/μL). As a minor 
adverse event, two patients complained of nasal soreness, 
but it was greatly relieved with a dose adjustment of the 
flow volume of oxygen.
With respect to the etiology of ARF, pneumonia 
(n  =  37) was a major cause of ARF, and only seven 
patients with CHF underwent HFNC in the present 
series. Indeed, 12 of the present patients with pneumonia 
Table 2 Risk factorsa for HFNC treatment failure
95 % CI 95 % confidence interval, HFNC high-flow nasal cannula, ARF acute respiratory failure, AKI acute kidney injury, allo-HSCT allogeneic hematopoietic stem cell 
transplantation, FDO2 fraction of delivery O2
a All statistical analyses were performed with EZR statistical software
b Disease risk was classified into two categories; high risk included acute leukemia not in remission, myelodysplastic syndrome with excess blast count or chronic 
myelomonocytic leukemia, the others were classified as low-risk
Univariate analysis Multivariate analysis
p value p value OR 95 % CI
Age (≥60 years) 1
Sex (male) 0.31
Neutropenia (yes) 0.02 0.81 1.40 0.09–20.8
Thrombocytopenia (<3.0 × 104/μL) (yes) <0.01 0.15 7.07 0.49–102
Disease risk (highb) 0.50
Cause of ARF (pneumonia) <0.01 0.01 11.2 1.76–71.5
Concomitant AKI (yes) 0.73
Concomitant liver dysfunction (yes) 0.71
Under allo-HSCT (yes) 0.05 0.52 2.13 0.21–21.7
Past history of cardiac disease (yes) 1
Past history of pulmonary disease (yes) 1
Past history of allo-HSCT (yes) 0.12
FDO2 (≥60 %) 0.26
Oxygen supplement volume before starting HFNC (≥10 L/min) 0.33
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(32 %) developed ARDS, and only 2 of 37 patients (5 %) 
with pneumonia had successful treatment, while 9 of 
19 patients (47  %) with other etiology recovered from 
ARF. Moreover, the present multivariate analysis clearly 
showed that pneumonia was a risk factor for treatment 
failure. Although Frat et al. (2015) showed more favora-
ble outcome of HFNC treatment in pneumonia patients, 
their study excluded patients with neutropenia. The per-
centage of pneumonia related to immunosuppression 
was as low as 6 %. Thus, the discrepancy is likely attrib-
utable to different characteristics of patient and disease 
profile. Although further clarification is needed regarding 
which patients with ARF should undergo HFNC therapy 
and which conditions of HFNC therapy to use, pneumo-
nia complicated with ARDS, which usually requires high 
pressure-PEEP for better management, might not be 
appropriate for HFNC therapy (Briel et al. 2010).
The present study had several limitations. The small 
size of the cohorts is one, and the retrospective nature of 
the study prevented the obtaining of missing data, includ-
ing the arterial blood gas level before and after HFNC, 
which would be important parameters for risk analysis or 
clinical judgement. Nevertheless, the focus was to outline 
the clinical utility of HFNC therapy for ARF in patients 
with hematological disease. Although, further clarifica-
tion is needed to determine whether HNFC therapy is 
better for patients with hematological disease with pro-
found immunosuppression or severe thrombocytopenia, 
our data should provide useful insights into this new 
device.
Conclusion
HFNC therapy was safe and well tolerated in patients 
with hematologic diseases who developed ARF, however, 
it appeared not to be a viable treatment option in 4 out 
of 5 patients and pneumonia could be the risk factor of 
treatment failure of HFNC.
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Fig. 1 Comparison of vital signs before and after initiating high-flow nasal cannula (HFNC). Heart rate (a), oxygen saturation level (b), and respira-
tory rate (c) were significantly improved after initiating HFNC (p < 0.01 in all parameters)
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